Canada: Supreme Court Of Canada Denies Authorization In First Quebec Secondary Market Securities Class Action

On April 17, 2015, the Supreme Court of Canada released its decision in Theratechnologies inc. v. 121851 Canada inc., the first case to consider the authorization of a secondary market class action under the provisions of the Quebec Securities Act that came into force in 2007. These provisions created a new statutory cause of action that enabled investors to bring claims against reporting issuers who breach their obligations to disclose material facts and changes; however, investors must obtain court authorization to commence such claims.

In a unanimous judgment, the Supreme Court held that the threshold for authorization to commence a secondary market action under the Quebec legislation requires showing "a reasonable or realistic chance that the action will succeed." The Court allowed the appeal, concluding that the evidence did not credibly point to any material change that could have triggered timely disclosure obligations for the reporting issuer; accordingly, there was no reasonable possibility that the action could succeed.


Theratechnologies Inc. ("Thera"), a TSX-listed pharmaceutical company, filed a new drug application with the FDA in June 2009 for tesamorelin. Throughout the following year, Thera issued press releases updating investors on the status of the FDA approval process and announcing results from its Phase 3 clinical studies. In particular, since tesamorelin triggers a hormone associated with increased risk of diabetes, Thera announced results from clinical trials indicating that the possible effects of tesamorelin on blood sugar were not clinically significant.

As part of the usual FDA approval process, an Advisory Committee meeting was scheduled for May 27, 2010. Prior to the meeting, Thera provided the FDA with a briefing package that contained a summary of the clinical trial results already disclosed to investors. On May 11, 2010, the FDA sent Thera its own briefing package, which included a list of questions about tesamorelin's side effects for the Committee's consideration. Thera did not issue a press release at this point. In accordance with FDA policy, the FDA published all briefing materials on its website prior to the Advisory Committee meeting, on May 25, 2010.

Stock quotation agencies such as Dow Jones reacted immediately to the questions in the FDA briefing package and issued press releases suggesting that the FDA was concerned that tesamorelin could increase diabetes risk. Thera did not issue a press release at this point. The trading volume of Thera stock on May 25 was unusually high, and the share price fell 58%. Thera's stock was cease-traded on May 27. The same day, the Advisory Committee unanimously voted to approve Thera's new drug application. Thera communicated this news to shareholders immediately, and its share price recovered on May 28.

The plaintiff, a holding company, sold its shares in Thera on May 25 following the Dow Jones press release at a loss of $271,752 relative to the previous trading day. The plaintiff sought authorization under s. 225.4 of the Quebec Securities Act ("QSA") to commence a secondary market class action. The plaintiff claimed that the FDA's May 11 questions about the potential side effects of tesamorelin amounted to a material change in Thera's business, operations or capital that should have been disclosed to investors.

The Quebec Superior Court held that the test under QSA s. 225.4 - whether the action has a "reasonable possibility of success" - is more stringent than the test for class action authorization. Even under this more stringent test, the Court granted authorization to commence a secondary market action.

The Quebec Court of Appeal upheld this decision. Justice Gascon, writing for the Court, held that the plaintiff had demonstrated a reasonable possibility of success because (i) it had identified a precise event that it alleged should have been disclosed, namely the questions posed by the FDA on May 11, and (ii) its theory of the case was supported by documentary evidence and explanations provided by the plaintiff on examination. Justice Gascon confirmed that the lower court was correct in not determining at the authorization stage whether the queries from the FDA could amount to a material change, as this determination should have been reserved for the trial on the merits.

The Supreme Court of Canada Decision

The Test for Authorization to Commence a Secondary Market Action

The Supreme Court of Canada agreed with the courts below that the test for authorization to commence a secondary market action is higher than the test for class action authorization, which in Quebec requires establishing only that "the facts alleged seem to justify the conclusions sought" or that the claim has "a good colour of right".

Justice Abella, writing for the Court, referred to the test for authorization to commence a secondary market action as "a meaningful screening mechanism" intended to prevent "costly strike suits and litigation with little chance of success". Accordingly, the test requires more than a mere possibility of success: it requires "a reasonable or realistic chance that the action will succeed". In turn, this requires the claimant to offer "both a plausible analysis of the applicable legislative provisions, and some credible evidence in support of the claim." The test should not be treated as a mini-trial, however, and "[a] full analysis of the evidence is unnecessary" at this stage. Ultimately, what is required is "sufficient evidence to persuade the court that there is a reasonable possibility that the action will be resolved in the claimant's favour."

In adopting this formulation of the test, Justice Abella relied on the legislative history of Ontario's statutory regime for secondary market liability, which served as the inspiration for similar legislation in other provinces including Quebec. Her Honour also endorsed Justice Belobaba's statement in Ironworkers Ontario Pension Fund (Trustee of) v. Manulife Financial Corp. that the threshold for leave to commence a secondary market action should be more than a "speed bump."


While the Supreme Court set out the same general test as the courts below, it went on to apply that test in a more stringent fashion. The Court concluded that the plaintiff had failed to point to any evidence of a material change in Thera's operations, capital or business that could trigger the requirement for timely disclosure.

The Court noted that Thera had consistently disclosed to its shareholders that it was monitoring tesamorelin's side effects, including on patients' blood sugar levels, and that any reasonable investor reading Thera's news releases would have known that blood sugar issues and diabetes were potential side effects of the drug that Thera's clinical trials had found not to be clinically significant. There was no evidence to suggest that the questions in the FDA briefing package of May 11, 2010 were anything more than routine inquiries by the FDA, or reflected any new and undisclosed information about tesamorelin.

The Court allowed the appeal, denying authorization to commence the proposed secondary market claim.

Implications of the Theratechnologies Decision

In Theratechnologies, the Supreme Court of Canada has confirmed that the test for authorization to commence a secondary market action requires a preliminary assessment of the merit of the claim based on a critical review of the evidence. The Court did not merely determine that the plaintiff had stated a valid legal claim and provided some evidence in support of the basic facts, as the courts below had done. Rather, the Court subjected the plaintiff's evidence to some scrutiny to determine whether the claim that Thera failed to disclose a material change had a realistic chance of success.

In Quebec, this decision is a positive development for public companies. The "realistic chance of success" threshold for secondary market liability proceedings is more stringent than the general test for authorization of a class action under section 1003 of the Code of Civil Procedure, which requires showing only a "colour of right". The "realistic chance of success" test, as applied by the Supreme Court in Theratechnologies, should provide some comfort to public companies and their insurers that they will be shielded from undue securities class action exposure.

The Theratechnologies decision is also the latest word from the Supreme Court regarding the meaning of a "material change" for purposes of securities legislation. The Court reiterated the holding from its 2007 decision in Kerr v. Danier Leather Inc. that not every external development affecting a public company's share price is a material change to the business, operations or capital of the company that triggers timely disclosure obligations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.